CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis1Part of this work was presented in abstract form at the Twenty-Seventh Annual Meeting of the Society for Neuroscience, October 25–30, 1997, New Orleans, LA, USA.1
| Autor: | Norbert Müller, Stephan Schmidt, Frank Padberg, T. Nolde, D.A. Körschenhausen, W Feneberg, Benjamin D. Greenberg, N König, H.-J. Möller, H Trapmann, Markus J. Schwarz, Harald Hampel |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
biology business.industry Multiple sclerosis medicine.medical_treatment Immunology Experimental autoimmune encephalomyelitis medicine.disease Glycoprotein 130 Cerebrospinal fluid Cytokine Endocrinology Neurology Internal medicine Interleukin-6 receptor medicine biology.protein Immunology and Allergy Neurology (clinical) Receptor business Interleukin 6 |
| Zdroj: | Journal of Neuroimmunology. 99:218-223 |
| ISSN: | 0165-5728 |
| DOI: | 10.1016/s0165-5728(99)00120-4 |
| Popis: | Interleukin-6 (IL-6) has recently been implicated in multiple sclerosis (MS), since IL-6 deficient mice were resistant to a demyelinating form of experimental autoimmune encephalomyelitis and IL-6 expression was upregulated in MS. The cytokine IL-6 and its action mediating soluble receptors (sIL-6R and sgp130) were measured in cerebrospinal fluid (CSF) and serum of 61 MS patients and 39 controls. In the presence of unchanged IL-6 concentrations, sIL-6R and sgp130 serum levels were significantly increased in MS and correlated with disease severity. Furthermore, sgp130 CSF levels were decreased in MS, suggesting a possibly altered IL-6 regulation in the CSF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect